Standout Papers

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease 2012 2026 2016 2021 816
  1. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease (2012)
    William J. Sandborn, Christopher Gasink et al. New England Journal of Medicine

Immediate Impact

10 from Science/Nature 77 standout
Sub-graph 1 of 18

Citing Papers

Refining the impact of genetic evidence on clinical success
2024 StandoutNature
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
2023 Standout
21 intermediate papers

Works of Christopher Gasink being referenced

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
2012 Standout
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial
2011
and 5 more

Author Peers

Author Last Decade Papers Cites
Christopher Gasink 1698 577 1085 941 90 2.1k
Bella Ungar 1776 480 1321 962 86 2.2k
Ella Fudim 1388 333 1004 984 50 2.0k
Fabian Schnitzler 2295 823 1749 886 42 2.9k
Masakazu Takazoe 1760 792 932 1177 74 2.7k
René Fiasse 1039 644 1094 356 108 2.0k
Koji Sawada 1091 248 836 753 104 2.0k
Per Karlén 2398 899 1801 417 46 3.1k
Yao He 1101 671 818 311 95 1.9k
Jean‐Marc Gornet 668 691 650 386 72 1.8k
Maria Nachury 952 818 649 509 80 2.0k

All Works

Loading papers...

Rankless by CCL
2026